+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using ID3 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using ID3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using ID3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded rat kidney tissues using ID3 mouse mAb with DAB staining.    

  
  

The ID3 antibody targets the Inhibitor of DNA Binding 3 (ID3) protein, a member of the ID protein family involved in regulating cell differentiation, proliferation, and survival. ID proteins lack a DNA-binding domain but modulate gene expression by binding to basic helix-loop-helix (bHLH) transcription factors, preventing their interaction with DNA. ID3. in particular, plays roles in immune regulation, stem cell maintenance, and tissue development. Dysregulation of ID3 has been implicated in cancers, including B-cell lymphomas, prostate cancer, and breast cancer, where its overexpression often correlates with tumor progression, metastasis, and poor prognosis. In B-cell malignancies, ID3 mutations or epigenetic silencing are linked to disrupted differentiation and chemoresistance.

ID3 antibodies have emerged as valuable tools for research, enabling detection of ID3 expression in tissues or cell lines to study its biological functions and disease associations. Therapeutic exploration of ID3-targeting antibodies is ongoing, with potential applications in blocking ID3-mediated oncogenic signaling or enhancing immune responses against cancer cells. Preclinical studies suggest that neutralizing ID3 activity may suppress tumor growth or sensitize cancer cells to conventional therapies. However, challenges remain in optimizing specificity, delivery, and minimizing off-target effects. Current research also investigates ID3's role in non-cancer contexts, such as cardiovascular and neurodegenerative diseases, broadening its biomedical relevance. While clinical applications are still experimental, ID3 antibodies continue to provide critical insights into both basic biology and therapeutic targeting of this multifunctional protein.